Lilly
Eli Lilly and Company
- HQ
- United States
- Status
- active
- Listing
- Listed · LLY
- Current stage
- commercial
- Key people
- Carole Ho (EVP and president, Lilly Neuroscience)
sec.govregistryverified 2026-11-02
Notes on the record
Acquirer in D001-lilly-ataibeckley-2026. Separately the sponsor of the brenipatide programme (A006), which is not part of that acquisition. Supersedes the row verified 2026-08-25. Merger closed 2026-09-11; AtaiBeckley Inc. is a wholly owned subsidiary. No Lilly 8-K on the closing as of 2026-09-15 (submissions API HTTP 200; the only September filing is a Form 4 for an unrelated 2025 transaction). Sponsor of record on six brenipatide CTIS records (A006), the sixth in asthma. RE-VERIFIED 2026-11-02, no field changed; key_people not re-read. EDGAR CIK 59478 (HTTP 200): Q3 8-K 0000059478-26-000104 (2026-10-29, Items 2.02 and 9.01) and Q3 10-Q 0000059478-26-000108 (2026-10-29), which books AtaiBeckley as an asset acquisition with a $2,610m acquired IPR&D charge (D001 row of 2026-11-02). Schedule 13D 0000059478-26-000095 (2026-10-16) is on TRex Bio, Inc., unrelated. Still no Lilly 8-K on the AtaiBeckley closing as of 2026-11-02. Supersedes the row verified 2026-09-15 (kept), per DATA LAYER rule 4.
Assets
Phase 3 in MDD (two pivotals) and alcohol use disorder (two pivotals); Phase 2 in bipolar disorder, IBS-D, IBS-C and asthma (CTIS 2025-522640-41-00, 52-week, authorised DE and FR 2026-01-21, PL 2026-01-30, NL 2026-02-02; recruitment started PL 2026-02-18) · major depressive disorder; alcohol use disorder; bipolar disorder; irritable bowel syndrome (IBS-D, IBS-C); uncontrolled moderate to severe asthma
euclinicaltrials.euregistryverified 2026-09-15
Registered trials
PHASE2 · Bipolar Disorder · RECRUITING · Argentina, Brazil, China, India, Japan, Mexico, Puerto Rico, United States
clinicaltrials.govctgov registryverified 2026-08-31
PHASE3 · Depressive Disorder, Major · RECRUITING · Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States
clinicaltrials.govctgov registryverified 2026-11-07
PHASE3 · Depressive Disorder, Major · RECRUITING · Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States
clinicaltrials.govctgov registryverified 2026-10-19
Therapeutic confirmatory (Phase III) · Depressive Disorder, Major · Authorised · Germany, Greece, Poland, Spain
euclinicaltrials.euctis registryverified 2026-10-19
Therapeutic confirmatory (Phase III) · Alcohol Use Disorder · Authorised · Belgium, Germany
euclinicaltrials.euctis registryverified 2026-11-07
Therapeutic confirmatory (Phase III) · Alcohol Use Disorder · Authorised · Belgium, Germany
euclinicaltrials.euctis registryverified 2026-08-31
Therapeutic exploratory (Phase II) · Irritable Bowel Syndrome Diarrhea · Authorised · Belgium, Germany, Poland, Spain
euclinicaltrials.euctis registryverified 2026-08-31
Therapeutic exploratory (Phase II) · Irritable Bowel Syndrome - Constipation · Authorised · Belgium, Spain
euclinicaltrials.euctis registryverified 2026-08-31
Therapeutic exploratory (Phase II) · Uncontrolled moderate to severe asthma · Authorised · Germany, France, Netherlands, Poland
euclinicaltrials.euctis registryverified 2026-09-15
PHASE2 · Pulmonary Disease, Chronic Obstructive · RECRUITING · Argentina, Austria, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Japan, Mexico, Poland, Puerto Rico, Romania, South Korea, United Kingdom, United States
clinicaltrials.govctgov registryverified 2026-09-28
PHASE3 · Alcohol Use Disorder · RECRUITING · Belgium, China, Germany, Japan, South Korea, Taiwan, United Kingdom, United States
clinicaltrials.govctgov registryverified 2026-11-07
PHASE3 · Alcohol Use Disorder · RECRUITING · Belgium, China, Germany, Japan, South Korea, Taiwan, United Kingdom, United States
clinicaltrials.govctgov registryverified 2026-09-28
PHASE2 · Irritable Bowel Syndrome; Constipation · RECRUITING · Belgium, Canada, China, Japan, Mexico, Spain, United Kingdom, United States
clinicaltrials.govctgov registryverified 2026-09-28
PHASE2 · Irritable Bowel Syndrome; Diarrhea · RECRUITING · Belgium, Canada, China, Germany, Japan, Mexico, Poland, Spain, United Kingdom, United States
clinicaltrials.govctgov registryverified 2026-09-28
PHASE2 · Asthma · RECRUITING · Argentina, Brazil, Canada, China, France, Germany, India, Japan, Mexico, Netherlands, Poland, United States
clinicaltrials.govctgov registryverified 2026-11-07
PHASE2 · Opioid Use Disorder · RECRUITING · Canada, Puerto Rico, United Kingdom, United States
clinicaltrials.govctgov registryverified 2026-11-07
Therapeutic exploratory (Phase II) · Pulmonary Disease, Chronic Obstructive · Authorised · Austria, Czechia, Germany, Denmark, France, Hungary, Poland, Romania
euclinicaltrials.euctis registryverified 2026-11-07
Deals
Eli Lilly and Company acquires AtaiBeckley Inc.
acquisition · closed · $3800m headline
sec.govsec filingverified 2026-11-02
In the briefing
6 issues tagged LILLY.